Novartis AG ADR buy melinda
Start price
30.07.17
/
50%
€77.06
Target price
20.09.17
€77.57
Performance (%)
0.91%
End price
20.09.17
€77.76
Summary
This prediction ended on 20.09.17 with a price of €77.76. The BUY prediction by melinda for Novartis AG ADR closed nearly unchanged. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | -0.633% | -0.633% | 1.073% | 30.110% |
| iShares Core DAX® | -1.347% | 3.576% | 14.229% | 18.356% |
| iShares Nasdaq 100 | 1.169% | 7.020% | 35.388% | 58.850% |
| iShares Nikkei 225® | -0.327% | -0.673% | 8.618% | 6.718% |
| iShares S&P 500 | 0.510% | 4.445% | 28.019% | 49.406% |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Zykadia (sNDA)
FDA Entscheidung über Zykadia als First-Line - Behandlung von Patienten mit Krebs der Lunge metastasierendem nicht-kleinzelligen (NSCLC) , deren Tumoren sind anaplastic lymphatische Kinase (ALK) - positiv
2017.08.23
FDA genehmigt den erweiterten Einsatz von Zykadia 26, Mai 2017